Search Results

The Maryland Oncology Hematology Chevy Chase office offers comprehensive, patient-centered care for individuals facing cancer and blood disorders. Located in the heart of Chevy Chase, this facility provides access to board-certified oncologists and hematologists who specialize in personalized treatment plans tailored to each patient’s unique needs. With a strong commitment to compassionate care and medical…

Jessica Adams has over 15 years of nursing experience. She worked as an inpatient solid organ transplant nurse in Washington, DC where she has developed expertise in providing complex, compassionate care to patients and their families. She has worked as a Nurse Practitioner since 2024. Jessica earned her Bachelor of Science in Nursing from the…

Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)(D9722C00001) MOA: Saruparib (AZD5305) is a selective inhibitor of PARP1, with…

Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer (EmpowHER 208) MOA: Zanidatamab is a HER2-targeted bispecific antibody against ECD2 and ECD4 domains of HER2 Key Eligibility: Stage II or III, tumor ≥2 cm, histologically confirmed BC Inflammatory BC (T4d) are eligible Bilateral BC excluded…

Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer (ORIC-944-01) MOA: ORIC-944 is a highly selective, allosteric, small molecule inhibitor of PRC2 via binding the EED subunit. Key Eligibility Criteria: Documented progressive metastatic prostate cancer Must have undergone bilateral…